Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2006-11-21
2006-11-21
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
Reexamination Certificate
active
07138147
ABSTRACT:
The present invention relates to arsenic sulfide compounds. The present invention also relates to pharmaceutical compositions useful for treating cancer, such as leukemia or lymphoma, which comprises an arsenic sulfide compound. The present invention further relates to methods for treating cancer, such as leukemia or lymphoma, using an arsenic sulfide compound. Finally, the present invention relates to processes for producing arsenic disulfide (As4S4).
REFERENCES:
patent: 132275 (1872-10-01), Gettings
patent: 232807 (1880-10-01), Dennett
patent: 3700498 (1972-10-01), Kanazawa et al.
patent: 4497780 (1985-02-01), Barin et al.
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 6720011 (2004-04-01), Zhang
patent: 6875451 (2005-04-01), Ellison et al.
patent: 2002/0013371 (2002-01-01), Warrell, Jr. et al.
patent: 2002/0183385 (2002-12-01), Ellison et al.
patent: 1061908 (1992-06-01), None
patent: 1061908 (1992-06-01), None
patent: 1079391 (1993-12-01), None
patent: 1081104 (1994-01-01), None
patent: 1119113 (1996-03-01), None
patent: 1121807 (1996-05-01), None
patent: 1122700 (1996-05-01), None
patent: 1131037 (1996-09-01), None
patent: 1133725 (1996-10-01), None
patent: 2 539 993 (1994-03-01), None
patent: 43 17 331 (1994-12-01), None
patent: 2 539 993 (1994-03-01), None
patent: 51-88620 (1976-03-01), None
patent: 11667 (1997-06-01), None
patent: WO 94/02108 (1994-02-01), None
patent: WO 95/01789 (1995-01-01), None
patent: WO 95/22336 (1995-08-01), None
“Diarsendisulfid As2S2”, Gmelin's Arsenic, 8thEdition, 17:417-422, 1952.
Arsen (III)-Sulfid As2S2, Gmelin's Arsenic, 8thEdition, 17:422-433, 1952.
Qi and Bi, “Method for removing As2O3from Realgar”, Chung Yao Tung Pao, 8(5):21-22, 1983.
“Letter on Historical Facts Regarding the Development of Ai Ling No. 1 and the Clinical Use of Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia and a Study of its Mechanism,” Heilongjiang Branch of the Chinese Medical Association, Mar. 27, 1998.
Wang et al., “Arsenic Trioxide and Melarsoprol Induced Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in a PML and PML-PARα Independent Manner,” Blood, 92(5):1497-1504, 1998.
Yuan et al., Journal of Traditional Chinese Medicines, vol. 13(8), Aug. 1988.
Zhang et al., “Discussion on methods for removing As involving use of yogurt”, Zhongguo Zhongyao Zaahi, 20(9): 537, 1995.
Yuan et al., “Exploring methods for purifying Realgar”, Chung Yao Tung Pao, 13(8): 17-21, 1988.
Yuan et al., “Research on traditional methods for Purifying Realgar”, Chung Yao Tung Pao, 13(8); 23-26, 1988.
“Realgar”, Chinese Pharmacorpia (I), Guangdong Science and Technology Publishing House, China, pp. 298-299, 1995.
Lu et al., “Effective treatment of AML-M3 (APL) and their remission maintenance with Realgar: A pilot clinical laboratory study on 38 patients”, Blood, 90(10 Suppl. 1, part 1), p. 416a, #1849, 1997.
Forkner et al., “Arsenic as a therapeutic agent in chronic myelogenous leukemia”, Jour. A.M.A., vol. 97, No. 1, pp. 3-5, 1931.
Stephens et al., “The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia”, Ann. Intern. Assoc. , vol. 9, 1488-1502, 1936.
Monfardini et al., “Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis”, Cancer, 31: 492-501, 1973.
Cuzick et al., “Medicinal arsenic and internal malignancies”, Br. J. Cancer, 45: 904-911, 1982.
Lee et al., “Induction of gene amplification by arsenic”, Science, 241: 79-81, 1988.
Wang et al., “Studies on chemically preventing leukemia”, Chung Hua Chung Liu Tsa Chih, 11(3);207-210, 1989.
Pershagen et al., “On the pulmonary tumorigenicity of arsenic trisulfide and calcium arsenate in hamsters”, Cancer Letters, 27:99-104, 1985.
Yamamoto et al., Tumorigenicity of inorganic arsenic compounds following intratracheal instillations to the lungs of hamsters, Int. J. Cancer, 40:220-223, 1987.
Andrea et al., “The PML and PLM/RARα Domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic”, Experimental Cell Research 229: 253-260, 1996.
Schenk, Handbook of Preparative Inorganic Chemistry, 1: 603, G. Brauer, Ed., Academic press, New York, 2ndEd., 1963.
Mervis, “Ancient remedy performs new tricks”, Science, vol. 273: 578, Aug. 2, 1996.
Chemical Abstract, 63-Pharmaceuticals, vol. 11, pp. 317, #111: 219272j and 111: 219276p, 1987-1991.
Lu et al., Study of Realgar in the treatment of acute promyelocytic Leukemia (APL)- a pilot clinical and labroatory study on 32 patients, China-Korea Medical Conference '97, 1997.
Dictionary of Inorganic Compounds, vol. 1, Ac-C10, IC-000667-IC-000671.
Germolec et al., “Arsenic induces over expression of growth factors in human keratinocytes”, toxicology And Applied Pharmacology, 141:308-318, 1996.
Shen et al., “Use of arsenic trioxide (AS2-O3) in the treatment of acute promyelocytic Leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients”, Blood, vol. 89, No. 9, pp. 3354-3360, May 1, 1997.
Chen et al., “In vitro studies on cellular and molecular mechanisms of arsenic trioxide (AS2-O3) in the treatment of acute promyelocytic Leukemia (APL): AS2-O3includes NB4cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RARα/PML proteins”, Blood, vol. 88, No. 3, pp. 1052-1061, Aug. 1, 1996.
Kasper et al., “Hepatic Angiosarcoma and bronchioloalveolar carcinoma induced by Fowler's solution”, JAMA, vol. 252, No. 24, pp. 3407-3408, 1984.
Cutler et al., Article IV, American Journal of the Medical Sciences, pp. 74-84.
Neubauer, “Arsenic Cancer: a review”, Arsenical Cancer, Arsenic Committee of the Medical Research Council pp. 192-251, 1947.
Zhu et al., “Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia”, Proc. Natl. Acad. Sci., vol. 94, pp. 3978-3983, Apr. 1997.
Hutchinson, “IX. Diseases, Etc., of the skin.”
“Goodman & Gilman's The pharmacological basis of therapeutics”, ninth edition, McGraw-Hill, Health Professions Division, pp. 1659-1662.
Huang, Shiling; Guo, Aixia; Xiang, Yang et al. 1995, “The Linic Study of QUINGDAI Tablet for Treating Acute Promyelocytic Leukemia”, China Magazine of Hematology, 16(1):26.
Xiang, Yang; Huang, Shiling; Guo, Aixia et al., 1995, “60 Cases of Treating Acute Promyelocytic Leukemia by QUINGDAI tablet,” Medical Magazine of the Liberation Army, 20(3):227-229.
“Inorganic Arsenic Compounds Other than Arsine Health and Safety Guide, Health and Safety Guide No. 708”, WHO, Geneva, 1992.
“Xionghuang”, Chinese Pharmacopia (I), Guangdong Science and Technology Publishing House, China, pp. 298-299, 1995.
Akao et al., “Arsenic Induces Apoptosis in B-cell Leukaemic Cell Lines in Vitro: Activation of Caspases and Down-regulation of Bcl-2 Protein”, British J of Hematology, 102. 1055-1060, 1998.
Arsenic, Environmental Health Criteria 18, Geneva: WHO 1981.
Chen et al., “Use of Arsenic Trioxide (AS2-O3) in the Treatment of Acute Promyelocytic Leukemia (APL): I. AS2-O3Exerts Dose-Dependent Dual Effects on APL Cells”, Blood, vol. 89, No. 9, pp. 3345-3353, 1997.
Chung et al. “Influence for Carcinoma Cell and Lymphatic cell of Acetyl Arsonate”, Yakhak Hoeji vol. 40, No. 5, pp. 599-607, 1996.
de Thè, “L'oyxyde d'arsenic: après l'acide rètinoique, un nouvea traitement ciblède la leucèmie aiguëpromyèlocytaire”, mèdecine/science; 13:867-71, 1997.
Flamigni et al., “Effect of Sodium Arsenite on the Induction and Turnover of Ornithine Decarboxylase Activity ub Erythroleukemia Cells”, Cell Biochemistry and Function, vol. 7:213-217, 1989.
F
Lu Daopei
Pryor Alton
LandOfFree
Arsenic sulfide compounds and derivatives thereof for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arsenic sulfide compounds and derivatives thereof for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arsenic sulfide compounds and derivatives thereof for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3687649